Kenvue cut its annual sales forecast on Thursday, as the consumer health company undergoes a strategic review aiming to boost ...

Kenvue forecast its annual profit below Wall Street estimates on Thursday, as it undergoes a strategic review, which ...

(Reuters) -Kenvue reported a second-quarter profit largely in line with Wall Street estimates on Thursday, amid a strategic ...

Kenvue Inc. shares fell 3.4% in premarket trading after the consumer health company reported second-quarter results that ...

(NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of ...

Kenvue CEO Thibaut Mongon has stepped down as the company’s chief executive and departed its board of directors. The CEO of ...

Kenvue says it will update shareholders as the strategic review progresses. Merlo added, “We are confident that the steps we are taking put Kenvue on the right path to deliver both near- and ...

EARNINGS: The Johnson & Johnson spinoff, which makes Tylenol and Benadryl, is expected to post a profit of $482.3 million, or 25 cents a share, according to analysts surveyed by FactSet. That compares ...

Kenvue says that Thibaut Mongon is stepping down as its CEO as the maker of Listerine and Band-Aid brands continues with a strategic review of the company. Kenvue used to be a part of Johnson ...

Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the company is considering simplifying its portfolio amid a recent ...

Tylenol maker Kenvue ousts CEO amid board's strategic review By Sriparna Roy and Abigail Summerville July 14, 20252:07 PM PDTUpdated July 14, 2025 ...